Tumor relapse is responsible for most breast cancer related deaths 1,2 . The disease recurrence stems from treatment refractory cancer cells that persist as minimal residual disease (MRD) for years following initial therapy 3 . Yet, the molecular characteristics defining the malignancy of MRD remain elusive due to difficulties in observing these rare cells in patients or in model organisms. Here, we use a tractable organoid system and multi-omics analysis to show that the dormant MRD cells retain metabolic peculiarities reminiscent of the tumor state. While the MRD cells were distinct from both normal and tumor cells at a global transcriptomic level, their metabolomic and lipidomic profile markedly resembled that of the tumor state. The MRD cells particularly exhibited a deregulated urea cycle and elevated glycolysis. We find the latter being crucial for their survival and could be selectively targeted using a small molecule inhibitor of glycolytic activity. We validated these metabolic peculiarities of the MRD cells in corresponding tissues obtained from the mouse model as well as in transcriptomic data from patients following neo-adjuvant therapy. Together, our results show that the treatment surviving MRD cells retain features of the tumor state over an extended period suggestive of an oncogenic memory. In accord, we found striking similarity in DNA methylation profiles between the tumor and the MRD cells. The distinction of MRD from normal breast cells comes as a surprise, considering their phenotypic similarity with regards to proliferation and polarized epithelial organization. The metabolic aberrances of the MRD cells offer a therapeutic opportunity towards tackling emergence of breast tumor recurrence in post-treatment care.
established a preclinical mouse model of breast cancer (see Methods) that bears doxycycline-inducible hMyc-and Neu/Her2-oncogenes [7] [8] [9] , which we have successfully used to isolate MRD relevant for human disease 10 . From these transgenic mice we obtain primary mammary cells to establish 3D organoid cultures 11 and are able to follow MRD establishment in phenotypic and molecular detail. In short, polarized structures lining a lumen represent the healthy tissue ( Fig.1a, left panel, Normal) , while addition of doxycycline at a dose of 200ng/ml (Extended data 1a-d) activates the expression of oncogenes, as shown for transgenic oncogenic-hMYC presence (Fig.1a , right panels, Tumor). This leads to uncontrolled proliferation as well as the loss of polarity and lumen (Fig.1a , left panels, Tumor). Removal of doxycycline from the media silences oncogene expression and triggers tumor regression, in line with the principle of oncogene dependence 12, 13 . Residual acini exhibit a re-polarized epithelium and absence of hMYC protein (Fig.1a , left and right panels, Residual), reminiscent to findings in mammary gland histological sections of the mouse model taken eight weeks after inducing tumor regression 10 .
Despite the phenotypic similarity of the residual spheres to normal acini, RNAsequencing data showed that the residual cells exhibit a distinct transcriptional profile ( Fig.1b , Extended data 2a). Gene-set enrichment analysis of differentially expressed genes in residual cells in comparison to normal cells resulted in Gene Ontology (GO) terms of "cell division and cell cycle", "cell signaling", and "response to stimuli" being enriched for downregulated genes and are in line with the observed dormancy of the residual cells (Extended data 2b, Supplementary table 1) . Genes connected to "cytoskeletal localization", "cell adhesion and movement" and "activation of cell surface receptor signaling" were upregulated, supporting the re-polarization process upon MRD establishment (Extended data 2c). Additionally, the growth supporting metabolic pathways of pentose phosphate pathway and glycolysis, were enriched for significantly upregulated genes and were found similarly upregulated in tumor cells (Extended data 2d, bottom- Supplementary table 2 ). Sub-setting the transcriptome to metabolic genes, the distinct PCA distribution patterns of the three populations observed in the global transcriptome were retained (Extended data 2e), suggesting altogether a potential metabolic abnormality of the surviving cells.
To examine the metabolic state of the three cell populations in detail, we embarked on lipidomic profiling as well as untargeted and targeted metabolomics analyses. Both intracellular and extracellular (culture supernatant) samples were analyzed to obtain a comprehensive overview of the metabolic (patho)physiology. We first optimized the metabolite extractions from 3D cultures (Extended data 3). Then we obtained profiles from shotgun lipidomics, which showed a surprisingly close similarity of residual and tumor populations ( Fig.1c ). This was also evident in the untargeted metabolomics analysis, with the regressed cells resembling tumor state and not the normal (Fig.1d ). Importantly, control samples obtained from wild-type mice lacking the reverse tetracycline-controlled transactivator (rtTA), but treated with doxycycline, clustered with the normal controls, thus excluding a potential confounding effect of doxycycline on the metabolism. Metabolomics analysis targeted at central carbon metabolism confirmed the results obtained from lipidomics and untargeted metabolomics, at the same time attesting that the dormant residual cells still retained key characteristics of their past tumorigenic state ( Fig.1e , Extended data 4a, Extended data 5). Notably, the residual cells aligned with the tumor in one of the universal cancer metabolic features, an enhanced glycolytic phenotype, as evident in decreased glucose pool sizes concomitant with increased levels of lactic acid (Fig.1f ). Another evident metabolic alteration prominent in the residual as well as in tumorigenic cells included an enhanced urea cycle activity shown by increased secretion of urea and ornithine ( Fig.1f ).
As changes in metabolite pools do not necessarily reflect flux changes, we used an integrative genome-scale metabolic modelling approach combining transcriptomics and extracellular metabolomics data with flux-balance analysis. In addition, we also performed reporter metabolite analysis 14 which integrates differential gene expression into the metabolic network to identify de-regulated metabolites (suggestive of changes in their turnover rate) (see Methods). Both genome-scale flux estimates and the reporter metabolite analysis corroborate the metabolite measurements confirming the upregulation of glycolysis and the urea cycle as major hallmarks of the residual cells. De-regulation of the urea cycle was confirmed by measured changes in other metabolites related to this pathway, including putrescine, proline, fumarate and aspartate (Extended data 5), with the latter two bridging also to the TCA cycle and nucleotide metabolism ( Fig.2 , Extended data 6). Furthermore, the data also brought forward a de-regulation of the pentose phosphate pathway, the TCA cycle, glutamine uptake and S-Adenosyl methionine (SAM) metabolism ( Fig.2 , Extended data 6). Together, the transcriptomics and metabolomics data, as well as flux modelling reveal significant metabolic peculiarities in the residual cell population reminiscent of the tumor state (compare Extended data 6 and 7).
We next asked to what extent these metabolic features of residual cells in the organoid system compare with the situation in mice and patients. Mouse mammary glands taken nine weeks following oncogene in-activation and subsequent successful tumor regression were compared to healthy glands obtained from age-matched control animals. Indeed, metabolic changes still persisted in the regressed tissue ( Fig.3a) as reflected in elevated extracellular levels of urea, ornithine and putrescine (Fig.3b ), a higher percentage of ARG1 positive cells ( Fig.3c , Extended data 8), higher levels on NO ( Fig.3d ) and higher flux to lactate (Fig.3e ). To assess the occurrence of such metabolic alterations in human patients, transcriptomic datasets of patient breast tissues after neoadjuvant treatment, were compared to breast tissues of healthy women. Notably, treated patient samples --based on genes in KEGG pathways being deregulated in cancer and involving HER2--clustered closely ( Fig.3f ) with the residual mouse samples (presented in Fig.1b ) and showed similar alterations in glycolysis and urea cycle compared to controls ( Fig.3g ). Additionally, alterations in these two pathways were also seen in the group of patient samples that were classified HER2 positive by histological analysis in the clinic (Extended data 9a) as well as in samples that clustered closely to mouse when the joint clustering was done based on all genes generally involved in HER2 or MYC related KEGG pathways (Extended data 9b, c). Taken together, these results support that changes in metabolism could be of potential relevance in clinical treatment 15 , which is specifically interesting for glycolysis 16, 17 and gives a working rational to test and re-purpose already approved metabolic drugs designed for primary tumor intervention 18 .
Therefore, we examined whether inhibition of glycolysis was affecting the robustness of the residual population. Indeed, treatment with 3-bromopyruvate (3-BP), a well-established inhibitor of glycolysis 19 induced cell death in residual cells grown in the absence of oncogenes for 10 days (Fig.4a , Extended data 10a, b). This cytotoxic effect was especially prominent at the dose of 50µM (within the common range used for tissue culture 20, 21 ) and also reflected in the morphology of the residual cell structures, but not of normal acini (Fig.4b , Extended data 10b). Increased cell death upon 3-BP treatment was also observed in the residual cells that were allowed to grow for 21 days in the absence of oncogenes expression ( Fig.4c ), reinforcing the notion of a "memory" carried over from the tumor state. Quantification of the extracellular metabolite pools revealed that the relative fold change in glucose concentration upon treatment (3-BP to control glucose ratio) was the most dramatic for the regressed population, especially at the 50-and 250 µM doses ( Fig.4d ), suggestive of a reduced glucose uptake. Consistently, beyond glucose, we additionally observed significant alterations in lactate pools and in glutamine levels in regressed cells following treatment (Extended data 10c). In comparison, normal cells were affected by 3-BP only to a minor extent. Together, the differences in cell death and glucose levels confirm the glycolytic nature of the residual cell population and its relevance as a targetable vulnerability.
As shown above, residual cells in vitro as well as MRD retain metabolic changes acquired during the tumor stage. Hinting at the mechanistic basis for this "oncogenic memory", we find that the residual cells resemble tumor cells also in their DNA methylation profiles ( Fig.4e ). Interestingly, certain metabolites that we found to be increased in the tumorigenic and residual populations (Extended data 5), like succinate, fumarate and nitric oxide, are also implicated in epigenetic modifications through direct inhibition of alpha-ketoglutarate dependent demethylases 22, 23 . Additionally, succinate, lactate and nitric oxide, all accumulated in tumor and residual cells, can operate as signaling molecules by binding and stabilizing proteins that further interfere with hypoxic signaling, including the stabilization of hypoxia inducible factor 1 (HIF1α), a well-known master regulator of the glycolytic phenotype in cancers [24] [25] [26] . Overall, the persistence of a tumor-associated metabolic signature in the residual population, despite the absence of continued oncogenic input, suggests that the accumulation of certain metabolites offers an additional survival advantage for MRD that is sustained through epigenetically-imprinted signaling pathways.
Taken together, our study offers a first in depth characterization of MRD derived from a primary organoid system that is relevant for human disease 10 . These findings can be validated in vivo by directly analyzing the residual mammary glands taken from the mouse model ( Fig.3a-e ). The residual cells, despite being characterized by a nonproliferative and histologically normal phenotype, harbor metabolic aberrations similar to that of the tumor cells. We refer to these changes as "oncogenic memory", which is reflected in metabolite levels, glycolytic flux and DNA methylation patterns, and persists in the face of an inactive oncogenic signal in residual cells. Since residual cells represent a treatment refractory population of dormant cancer cells, tackling these memorized cancer hallmarks offers a unique therapeutic opportunity. We consequently illustrate how the interference with one of these metabolic nodes, viz., glycolysis, specifically targets the survival of residual cells. We envisage that the identified transcriptional, metabolic and epigenetic distinctiveness ( Fig.4f ) of MRD will offer novel long-term treatment options for targeted interference to block the progression towards tumor relapse.
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Figure 1: Multi-omics approach reveals characteristic features of residual structures in vitro and their metabolic resemblance to the tumor. a,
Immunofluorescence staining of normal, tumor and residual structures. Left panel: polarity markers ITGA6 (red), ZO-1 (green), GM-130 (magenta); DAPI (blue). Right panel: human MYC oncogene (green); CDH1 (red). Scale bar: 25 μm. b, c, PCA analysis of normal (blue), tumor (orange) and residual (green) populations based on RNA sequencing data (b, normal n=8, tumor and residual n=4) and Lipidomics data (c, n=4). d, Heat map of untargeted metabolomics results showing the clustering of the three populations along with the most altered metabolic pathways (n=4). Hierarchical clustering was based on the complete linkage method using the Euclidean distance metric. Significance thresholds correspond to a p-value < 0.05 calculated using unpaired two-sided t-tests and adjusted for multiple hypothesis testing 27 in comparison to the normal population. PPP, pentose phosphate pathway; TCA, tricarboxylic acid cycle; OXPHOS, oxidative phosphorylation; AA amino acid. e, PCA analysis of normal and WT (blue), tumor (orange) and residual (green) populations based on intracellular metabolomics measurements targeted at central carbon metabolism (n=8; WT n=2). f, Selection of the most profoundly altered metabolites in extracellular spent growth media of normal (N and WT, n=4 and n=2, respectively), tumor (T) and residual (R) populations (n=4). The results are based on a metabolomics analysis targeted at central carbon metabolites. The values represent metabolite abundance levels as quantified by the area under the curve (AUC) of the corresponding ions for each metabolite. a-f, Number of replicates corresponds to different animals. b, c, e, Centroids represent the mean and concentration ellipses one standard deviation (level=0.68) of an estimated t-distribution based on the first two principal components. f, Box plots: midline, median; box, 25-75th percentile; whisker, minimum to maximum. Statistics are calculated using the limma package 28 in R with the significance threshold corresponding to a Benjamini-Hochberg adjusted p-value ≤ 0.01 and a log2 fold change (residual or tumor compared to normal) ≥ 1 or ≤ -1.
Figure 2: Global overview of altered metabolic pathways in residual cells, compared to normal.
A selection of genes with significantly altered expression (Wald test 29 , Bonferroni adjusted p-value < 0.1; normal n=8, tumor and residual n=4), targeted metabolites with significantly altered levels (Benjamini-Hochberg adjusted p-value < 0.01; n=8; WT n=2) and significant reporter metabolites (top 5% with p-value < 0.1) of core metabolic processes are presented. Metabolites with an additional log2 fold change ≥ 1 or ≤ -1 are highlighted in bold. A Wald test with a Negative Binomial GLM was used as test statistics for gene expression and for metabolite levels. For the reporter metabolites a gene set enrichment analysis was performed from a theoretical null-distribution using the reporter method 30 . Bonferroni adjusted p-values of the expression analysis were used as gene-level statistics. Metabolite-gene sets were derived from a genome wide human metabolic model (HMR2), with genes mapped to mouse orthologs 31 . Flux balance analysis predicted metabolic fluxes, which are altered in the corresponding pathways, are overlaid. Significantly altered gene expressions and metabolites were used to inform the predictions. Number of replicates corresponds to different animals. Representative images of immunofluorescence staining in normal (top) and residual (bottom) duct stained for ARG1 (green); CDH1 (red), DAPI (blue). Scale bar: 20 μm. d, NOS activity in healthy (n=3) and regressed (n=3) mammary glands. e, Fractional labeling of lactate following cultivation of isolated regressed (n=3) and healthy (n=3) mammary glands in cell growth media supplemented with [U-13 C] glucose for 8 hours. The three-carbon labeled ( 13 C) isotopologue (M+3) is depicted. f, Joint clustering of mouse model (RNA-seq, normal n=8, residual n=4) and patient (microarray, healthy n=10 samples, residual n=20 samples) derived transcriptome log2 fold changes of healthy samples compared with regressed tumor samples. The clustering is based on all genes of KEGG pathways, which involve HER2 and are known to be deregulated in cancer. Hierarchical clustering with the complete linkage method and the Euclidean distance as a distance metric was used for clustering. For the patient comparison, two independent data sets, one obtained from healthy breast tissue (GSE65194) 32, 33 and one obtained from patient tissues after neoadjuvant treatment (GSE32072) 34 , were merged. g, Metabolic reactions of glycolysis and urea cycle, which are catalyzed by enzymes with differential expression (Benjamini-Hochberg adjusted p-value < 0.1), are highlighted in red. An empirical Bayes moderated t-statistics was computed from a gene wise linear model fit with generalized least squares 28 , comparing the treated patients (n=4 samples), which are clustering closely with the mouse samples (f), with healthy breast tissue (n=10 samples). Differential expression from mouse in vitro transcriptome data of residual versus normal samples (RNA-seq, normal n=8, residual n=4) is shown in comparison (Wald test, Bonferroni adjusted p-value < 0.1) 29 . a-f, Number of replicates corresponds to different animals, b-e, Box plots: midline, median; box, 25-75th percentile; whisker, minimum to maximum. b, Statistics are calculated using the limma package 28 in R with the significance threshold corresponding to a Benjamini-Hochberg adjusted p-value ≤ 0.01 and a log2 fold change (regressed or tumor compared to healthy) ≥ 1 or ≤ -1. d, e, The difference is statistically significant by unpaired two-samples t-test with p-values equal to 0.0136 and 0.0115, respectively. Clustering is based on fold changes of the sample wise calculated test statistics for the individual KEGG pathways of residual cells compared to normal. d, Heatmap with rlog transformed and gene-wise centered and scaled (stdv = 1) transcript counts of genes from glycolysis and pentose phosphate pathway. e, PCA analysis of transcriptome data sub-setted to metabolic genes, extracted from the mouse orthologs associated with the genome wide human metabolic model HMR2 31 . Centroids represent the mean and concentration ellipses one standard deviation (level=0.68) of an estimated tdistribution based on the first two principal components. a-e, Number of replicates (normal n=8, tumor and residual n=4) corresponds to different animals. a-d, Hierarchical clustering with the complete linkage method and the Euclidean distance as a distance metric was used for clustering. a, d, e, Sample labels: normal -blue, tumor -yellow, residual -green.
Extended data 3: Set-up of metabolic methods for 3D cultures. a, Primary epithelial cells obtained from mouse mammary glands are grown in matrigel, which enables growth in 3D and formation of hollow acini, schematic b, Timeline of experiment showing period of growth, tumor induction (5 days on doxycycline) and tumor regression (after doxycycline withdrawal, 7 days off). Experiments were designed in such a way that the metabolites from all three conditions (normal, tumor and residual) were harvested at the same endpoint after matrigel digestion. c, Total ion chromatograms showing a strong matrigel signal when no digestion is performed for the collection of structures (1), and an improved signal of intracellular metabolites after gel digestion (2), representative example. expression analysis (Wald test) were used as gene-level statistics. Metabolite-gene sets were derived from a genome wide human metabolic model (HMR2), with genes mapped to mouse orthologs 31 . Flux balance analysis predicted metabolic fluxes, which are altered in the corresponding pathways, are overlaid. Significantly altered gene expressions and metabolites were used to inform the predictions. Number of replicates corresponds to different animals.
Extended data 6: Global overview of altered metabolic pathways in tumor cells, compared to normal in an extended representation.
A selection of genes with significantly altered expression (Bonferroni adjusted p-value < 0. Genes with less than 10 counts across all samples were filtered to increase the sensitivity of the detection of differential gene expression. Package defaults were used for dispersion estimation and differential expression analysis with the function "Deseq", which includes independent filtering, cooks cutoff 8 Additionally, a reporter metabolite analysis was performed to identify metabolites or metabolic pathways that are likely to be de-regulated. Therefore, the q-values and log2
Materials and Methods
Animals. Breeding and maintenance of mouse colony was done in LAR (Laboratory
fold changes (FC) of the respective differentially expressed genes were used to calculate p-values from a theoretical null distribution (10000 permutations) utilizing the reporter metabolite algorithm from the "piano" R package 10 . Multiple testing adjustment was applied using the Benjamini-Hochberg procedure. The threshold for significance was padj-value < 0.01 for the non-directional class, the distinct-directional class and the mixed-directional class, but maximally the top 5% of the total list of tested metabolites considering each class equally. Pathway enrichment was calculated for gene sets of 1 gene per group or bigger. The gene set was obtained from a revised version of the HMR2 model 11 and is formulated as two-step linear optimization problem. The first step optimizes the agreement between relative enzyme usage and relative gene expression, and the second adds a parsimonious enzyme usage criterion.
Step 1:
Step 2:
Where a and b are two experimental conditions, e a and e b are the gene expression in each condition, v a and v b are reaction flux vectors, u a and u b are enzyme usage vectors, S ext is the extended stoichiometric matrix, umin is a flux activation threshold (set to 0.001), and ɛ is a relaxation term with regard to the first objective (set to 0.1).
Genome-scale metabolic modeling. Transcriptomics and extracellular GCMS
metabolomics data from this study were used as model inputs to refine the phenotype predictions performed with flux balance analysis. The transcriptomics data were provided as log2 fold changes of significantly differentially expressed metabolic genes (q-value < 0.1) between the two experimental conditions. The metabolomics data were used to constrain the metabolite uptake/secretion rates in the model, both in terms of absolute as constraints in the model with a deviation tolerance of 50% to account for measurement error. For metabolites whose level did not significantly change between conditions, absolute constraints were imposed to ensure a minimum level of uptake/secretion in accordance with the observed directionality. Measurements from pure media allowed determining active secretion/uptake of metabolites into/from the media in respect to both conditions.
A revised version of the human genome-scale metabolic model HMR2 (14) was used for simulation, in which mouse gene orthologs of the gene-protein-reaction annotations had been updated/corrected as well as the model itself to yield more accurate flux predictions.
In brief, this included the introduction of a mitochondrial intra-membrane space (adapted The dried metabolite extracts were stored at -80 o C until metabolomics analysis. Metabolite extraction from the spent growth media was performed as described above by adjusting the volume of the extraction solvents to 100 µl of HPLC-grade methanol and 100 µl of MilliQ water. Finally, 50 µl of the initial pure growth media as well as from the last washing solution were collected and extracted as described above, with the latter sample employed as control to validate the effective washing of the organoids from the extracellular media before quenching. (Phenomenex, USA). 1 µl of sample was injected in split mode (split ratio 1:10) at 250 0 C using helium as a carrier gas with a flow rate of 1 ml/min. GC oven temperature was held at 100 0 C for 4 min followed by an increase to 320 0 C with a rate of 10 0 C/min, and a final constant temperature period at 320 0 C for 11 min. The interface and the ion source were held at 280 0 C and 230 0 C, respectively. The detector was operated both in scanning mode recording in the range of 50-600 m/z, as well as in MRM mode for specified metabolites.
In vivo and ex vivo mammary glands experiments.
The metabolite identification was based on an in-house database with analytical standards being utilized to define the retention time and the mass spectrum for all the quantified metabolites. The metabolite quantification was carried out by calculating the area under the curve (AUC) of the marker ion of each metabolite normalized to the AUC of adonitol's marker ion 319. Subsequently, the AUCs were normalized to total metabolite levels. To identify the statistically significant altered metabolites the limma package 22 until GC-MS analysis. The GC-MS was operated using the same conditions as described above with the following difference: GC oven temperature was held at 100 0 C for 3 min followed by an increase to 300 0 C with a rate of 3.5 0 C/min, and a final constant temperature period at 300 0 C for 10 min. The natural abundance isotopes were corrected using the Isotope Correction Toolbox (ICT) 27 . Statistics were calculated by unpaired two-samples ttest following assessment of normality and equal variance using the Shapiro-Wilk's test and F test, respectively.
Untargeted metabolomics by flow injection mass spectrometry. Untargeted metabolomics analysis was performed based on a previously published approach 28 Lipidomics. Acidic extractions were performed as described 31 Images were taken over time-course of the experiment from using the high-throughput
Olympus ScanR microscope in transmission mode. Each well of the 96-well plate was imaged using 1 ROI per with 21 Z-stacks (100 µm distance between stacks) at 4X magnification in a chamber with standard conditions (37 °C, 5% CO2). Projections of zstacks and image stitching was done using a Fiji software.
DNA methylation profiles. After digestion of the Matrigel with collagenase and liberase,
DNA was collected from the 3D cultures and extracted following Qiagen protocol for cultured cells (Qiagen Blood & Cell Culture DNA Mini kit, 13323). Bisulfite-free sequencing was performed at the Genomics Core Facility at EMBL Heidelberg.
Sequencing reads were aligned with the "qAlign" function of the R package "QuasR" version 34 (rand the parameter setting modification: bisulfite="undir". Next, the DNA methylation was genome-wide quantified for all cytosine nucleotides in CpG context with the function "qMeth" from "QuasR" using the information from both strands combined. R V.3.5.1. (R Development Core Team) was used for conducting biostatistical analyses.
